Stock NURO NEUROMETRIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News NeuroMetrix, Inc.

Equities

NURO

US6412558800

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
4.33 USD -2.46% Intraday chart for NeuroMetrix, Inc. +21.29% +20.28%
Apr. 19 Sector Update: Health Care Stocks Advance Late Afternoon MT
Apr. 19 Sector Update: Health Care Stocks Rise Friday Afternoon MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care Stocks Rise Friday Afternoon
MT
NeuroMetrix Says Joshua Horowitz Joining Board, Terminates At-the-Market Equity Facility
MT
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
AQ
Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board
CI
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
AQ
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
AQ
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
CI
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
AQ
Ephraim Fields Discloses his Views on NeuroMetrix
CI
RS Fund Discloses its Views on NeuroMetrix
CI
Transcript : NeuroMetrix, Inc., Q4 2023 Earnings Call, Feb 22, 2024
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
AQ
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
AQ
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
CI
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
AQ
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
AQ
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NURO Stock
  4. News NeuroMetrix, Inc.